Sponsor Chan Zuckerberg Biohub Network and the Chan Zuckerberg InitiativeDue Date November 13, 2025 ...

Sponsor Chan Zuckerberg Biohub Network and the Chan Zuckerberg InitiativeDue Date November 13, 2025 ...

The network provides high-quality brain tissue to scientists and clinicians and supports major initiatives on research into neurological disorders, including the aims of the Ministerial Action Group ...

This interactive resource organizes decades of data on biomarkers for Alzheimer's disease. Biomarker measurements from the cerebrospinal fluid and blood are curated from the primary literature and ...

THY-Tau22 mice are a model for tau aggregation, a pathological hallmark of Alzheimer's disease as well as numerous tauopathies. With age these mice develop a variety of tau-related neuropathological ...

Plasma p-tau217 has rapidly pushed to the forefront of Alzheimer’s biomarkers, proving as accurate at predicting plaques as amyloid PET. However, it is less clear how well this blood marker stacks up ...

This active vaccine was designed to overcome the weak immune system of aged populations while avoiding auto-immune T cell responses. The Lu AF20513 epitope intersperses three repeats of the first 12 ...

This approach uses mesenchymal stem cells isolated from a patient’s own fat tissue to treat neurodegenerative diseases. The stem cells are supposed to assist in repair of damaged tissue and ...

Species: Mouse Genes: SNCA Modification: SNCA: Transgenic Disease Relevance: Parkinson's Disease Strain Name: B6;DBA-Tg(Thy1-SNCA)61Ema Genetic Background: (C57BL/6 x DBA/2)F1 (strain of origin) ...

Finding genetic variants associated with Alzheimer’s disease has been easier than figuring out exactly how they heighten risk. In the September 3 Nature, scientists led by Jubao Duan at the University ...

With amyloid immunotherapy in clinical use, scientists need to find better ways to identify the patients most at risk of developing ARIA (see part 16 of this series). One of the biggest danger signs, ...

While amyloid immunotherapy is slowly becoming more accepted in clinical use, its biggest drawback remains the risk of ARIA. Scientists continue to study which patients are most at risk, how to ...